ERBB2 and breast carcinoma: More trials are assessing novel monoclonal antibodies (MoAbs), small molecule tyrosine kinase inhibitors (TKIs), and antibody drug conjugates (ADCs) as the third-line and beyond therapy for ERBB2-positive advanced breast cancer.